Intermittent claudication deteriorates in no more than 25% of patients. Distance walked on a treadmill is not a precise indicator of outcome, because the same impairment may result in severe limitation for one patient, but may not affect quality of life as judged by another. Only 18% of claudicant patients require surgical revascularization over 10 years, and smoking and ankle-brachial index are the most important markers of this type of surgery. Progression of claudication in critical leg ischaemia varies from 3·8% to 25% (5-year follow-up) and to 41% (8-year follow-up), and the amputation rate is approximately 10% (10-year follow-up). Inflammation and endothelial dysfunction appear to be the major risk factors for progression, but their occurrence is unpredictable and differs from patient to patient; consequently, further studies are required to clarify these aspects. (Eur Heart J Supplements 2002; 4 (Suppl B): B41-B45)
Introduction
Intermittent claudication is the main symptomatic expression of peripheral arterial disease, which is usually a sign of widespread atherosclerosis. Therefore, an appreciation of cardiovascular morbidity and mortality, and fate of the claudicant limb is important in understanding the natural history of this condition.
Although there is a large body of evidence that intermittent claudication is associated with high cardiovascular morbidity and mortality [1] [2] [3] [4] [5] , very few studies have examined the fate of the claudicant limb. In most studies the progression of local disease was measured in terms of number of amputations required or limbs developing critical ischaemia. However, chronic limb ischaemia occurs across a spectrum of severity, and both amputation and critical ischaemia are expressions of the most advanced stages of the ischaemic process. Deterioration in claudication symptoms and walking performance has been evaluated in other studies; however, assessment was mostly conducted by interview or validated questionnaires. This is particularly unfortunate because intermittent claudication is a condition especially suited to objective non-invasive evaluation.
The present review addresses the fate of the claudicant limb in terms of walking capacity and disability; operation rate; progression to critical limb ischaemia; and amputation rate.
Walking capacity and disability
Peripheral arterial disease is a relatively benign condition in terms of local disease. In a classic study [6] , 104 patients were observed for a mean of 2·5 years and it was found that the condition of 79% of the patients either improved or did not worsen. Similarly, a s tudy of 100 patients with intermittent claudication observed for 1-18 years (mean 6 years) showed that 78% improved or were stabilized [7] . In a more recent study [3] , 112 patients were monitored for a median of 82 months, and of the survivors 66% were symptomatically improved or stable; the technique used to evaluate the symptomatology was not reported, however. In order to eliminate subjective interviewing bias, in another study [8] patients completed written questionnaires, and walking distance was classified by clinical criteria. At the initial examination, 75% of the patients exhibited 'mild' intermittent claudication, defined as ability to walk at least 150 m without pain. After a mean follow-up of 31 months, the number of patients able to walk such a distance without pain reduced to 31%. The conclusion was that 60% of the patients categorized their symptoms as 'worsened', whereas 40% categorized their intermittent claudication as the 'same' or 'improved'. Moreover, the condition of 50% of patients above 60 years of age deteriorated in another study [9] .
To t he best of our knowledge, only one study [5] investigated deterioration of symptoms in terms of objective measures of intermittent claudication. Of 110 patients included in the study, 85 were able to exercise on a treadmill. After 24·4 months of follow-up, assuming a 30% change in maximal walking capacity as clinically relevant, 26% of the patients worsened, 27% improved and 47% remained stable. In another study, Dormandy and Murray [10] recruited 1969 patients predominantly from non-surgical hospital clinics, and observed that only 6% deteriorated over the first year.
In summary, all of the evidence obtained over the past 40 years, with the exception of only a few studies, has not altered the impression that not more than one-quarter of patients with intermittent claudication will experience deterioration of the symptomatology, and that deterioration is most frequent during the first year after diagnosis (i.e. 6-9%, compared with 2-3% per annum thereafter) [11] . Discrepancy between studies may be due to differences in severity of intermittent claudication among the patients enrolled and in the criteria used for symptom evaluation.
It is noteworthy that the distance walked on the treadmill does not reflect the degree of disability experienced by the patient in daily life [12] . This is because the same impairment in walking capacity may result in severe limitation for one patient, but may not affect quality of life as judged by another. Therefore, the evaluation of severity of claudication requires a comprehensive approach, using both objective e x e rcise testing and 'patient-focused' clinical outcomes [13] . Hence, there is a need for further studies using validated questionnaires, which probably represent the most accurate method with which to assess the change in disability over time.
Operation rate
Revascularization for peripheral arterial disease with bypass surgery, percutaneous transluminal angioplasty and stent placement is generally considered effective in increasing blood supply to the affected limb and in improving quality of life [14] . These procedures should be adopted only for limb salvage in patients with critical limb ischaemia, or in claudicant patients with severe functional impairment in whom c onservative t herapy failed to relieve d isability. During 1990, in the U.S.A more than 400,000 patients were hospitalized for peripheral artery disease, including an estimated 50,000 angioplasties and 110,000 bypass operations [15, 16] .
The reported studies vary widely in the percentage of claudicant patients who require interventional therapy, depending largely on the characteristics of the patients enrolled and the criteria for advising surgery. Table 1 shows the percentage of patients who required reconstructive surgery exclusively for disabling claudication.
In a prospective study of 513 patients with intermittent claudication, Breslau et al. [17] reported that reconstructive surgery was performed in only 3% of limbs over a 5-year follow-up period. Another 5-year follow-up study conducted in 400 patients with stable claudication [18] reported that 6% had reconstructive surgery. O'Riordain and O'Donnell [3] reported that 6·5% of patients were treated surgically after a mean follow-up of 82 months.
A higher operation rate was observed by Cronenwett et al. [8] , who reported that 7·6% of patients required surgery for disabling claudication, but after a mean follow-up period of 25 months. In that study, factors such as age, race, smoking, exercise, diabetes, hypertension and anklebrachial index (ABI) were analyzed to determine whether those variables could predict clinical outcome. Only cigarette smoking, exercise and ABI were significant in this regard. Patients who had smoked at least 40 packets a year had an operation rate 3·3 times higher than those who smoked less. Major daily exercise was associated with stable claudication. The initial ABI did not correlate with clinical outcome. Conversely, a subsequent decrease in the ABI of at least 0·15 was associated with an operation rate that was 2·5 times higher. The other variables were not significant predictors of subsequent reconstructive surgery.
In a more recent study [5] , reconstructive surgery was performed in 4·7% of 110 claudicant patients after a mean follow-up period of 24·4 months [5] . This figure is in accord with that reported in one of the earliest studies on the natural course of intermittent claudication [6] and with that reported by Muluk et al. [19] in a very recent study in which revascularization procedures occurred with a 10-year cumulative rate of 18%. Imparato et al. [6] 104 6-96 5·8 Cronenwett et al. [8] 91 6-72 7·6 Gilliand et al. [18] 100 66 6 Breslau et al. [17] 513 60 3 O'Riordain and O'Donnell [3] 112 82 (median) 6·5 Brevetti et al. [5] 110 6-54 4·7 
Progression to critical limb ischaemia
The term 'critical limb ischaemia' (CLI) is used for patients with chronic ischaemic rest pain, ulcers or gangrene attributable to objectively proven peripheral arterial disease.
In several trials [20] [21] [22] [23] , however, inclusion criteria for CLI included ankle pressure below 50-70 mmHg, toe pressure below 30-50 mmHg, or transcutaneous oxygen pressure below 30-50 mmHg. For most of these patients, in the absence of significant haemodynamic improvement, the outcome is surgical intervention or major amputation within 6 months to 1 year. The long-held view that intermittent claudication has a benign prognosis in terms of progression of peripheral arterial disease to CLI has been confirmed by many studies. One of the few studies that showed a higher rate of progression to CLI was reported by Rosenbloom et al. [2] , who reported that 24% of 310 claudicant limbs progressed to CLI after 5 years of follow-up, and 41% after 8 years. Jelnes et al. [1] reported that only 7·5% of claudicant patients worsened to critical ischaemia within the first year after referral, with a rate of 2·2% each year thereafter. In a more recent study [3] , 112 claudicant patients were monitored for a minimum of 5 years (median 82 months), and only 13% progressed to CLI. An Italian study [5] reported that 3·8% of claudicant patients progressed to CLI after 6-54 months of follow-up. A prospective 7-year study conducted in 200 patients with intermittent claudication and 190 control individuals [24] showed an incidence of CLI of 450 per million per year. Consistent with this, the Vascular Surgical Society of Great Britain and Ireland found an annual incidence of 400 cases per million per year [25] .
Apart from age, the most important predictors for CLI progression are smoking and diabetes. The risk associated with smoking applies to all ages and increases with the number of cigarettes smoked [8] ; major peripheral arterial disease deterioration occurs in heavy smoking claudicant patients [8, 26] . Diabetes appears to have more importance for progression than for initial development of symptoms of peripheral arterial disease. Patients with intermittent claudication and diabetes have a 35% risk for deterioration [27] ; this risk is double that in claudicant patients without diabetes [1] . Consistently, CLI deteriorates to gangrene in 40% of diabetic patients as compared with 9% of nondiabetic patients [28] .
A prospective study of conducted in Italy in 574 patients with CLI who were recruited on the basis of clinical findings (rest pain and/or trophic lesions) [29] revealed that after 3 months of observation 17·9% had persistent CLI, 12·2% had undergone a major amputation and 8·7% had died.
Amputation rate
Only a few studies have reported a high rate of amputation in selected populations of claudicant patients: 7% at 5 years and 12% over 10 years [2, 30] . More recent studies suggest major amputation is a relatively rare outcome in intermittent claudication, with only 1-3% of claudicants requiring such an intervention over a 5-year period [17, 18] . A retrospective study of 2777 patients with claudication showed that major and minor amputation had a 10-year cumulative rate of less than 10% [19] . Both the Basle study [31] and the Framingham study [32] , which are two large-scale studies that evaluated non-selected patients, found that fewer than 2% of claudicant patients required major amputation.
The notion that, in patients with poor outcome, amputation represents the final step of a process of progressive deterioration of severe intermittent claudication is generally incorrect. Indeed, out of 713 patients who received a below-knee major amputation, more than half had no symptoms of leg ischaemia as recently as 6 months previously [33] . This is because an acute onset of CLI is associated with a particularly poor prognosis. In the U.K. the number of patients undergoing major amputation for progression of claudication is 300 per million per year [34] .
The most important risk factors for amputation are the same as those that are involved in the progression to CLI.
Smoking as associated with a major amputation rate of 11% in claudicant patients [35] , and diabetes is associated with a 21% risk of amputation as compared with 3% in nondiabetic persons [28] . Another important predictor of amputation is a low ABI. In a prospective trial of nearly 2000 claudicant patients that was conducted to identify predictors of the need for arterial surgery or major amputation [10] , the most significant predictor was an ABI below 0·5. This in accord with the finding reported by Jelnes et al. [1] that an ABI below 0·5 is associated with a major risk of amputation, whereas no patients with an ankle pressure above 70 mmHg at the first visit had an amputation during the 6·5 years of observation.
Inflammation, endothelial dysfunction and progression of peripheral arterial disease
Peripheral arterial disease is associated with low-grade inflammation, as determined by leucocyte activation [36] , and increased levels of fibrinogen [37] , C-reactive protein [38] and interleukin-8 [39] , as well as with endothelial dysfunction in the affected limb [40] . These changes are common to any chronic atherosclerotic process. However, repeated episodes of ischaemia, as occurs each time the claudicant patient walks, may further enhance the inflammatory process in the blood vessels and thus may play a role in the progression of local disease. Indeed, intermittent claudication is associated with increased thrombin formation [41] , increased activation of neutrophils [42] and release of mediators [43] that may further impair endothelial function. Increased levels of thrombin enhance the pro-thrombotic potential. Activated neutrophils may injure the vessels distal to an obstruction in a way that promotes endothelial dysfunction or vascular injury, thus leading to the propagation of the atherosclerotic process. Finally, repeated episodes of acute exacerbation of chronically inflamed atherosclerotic tissue may be a trigger for endothelial erosion and destabilization of pre-existing plaques that may evolve with superimposed thrombosis [44] . Although it may be quite relevant in many patients, this scenario obviously may not be generalized. As illustrated above, peripheral arterial disease deterioration is rare in patients with intermittent claudication. The individual inflammatory response may vary, and genetic factors may predispose to or protect against vessel injury. The preliminary results of an ongoing study show that not all claudicant patients have a n inflammatory status at rest (Andreozzi GM, Martini R, unpublished data). Exercise induces inflammatory activation that is characterized by two responses: one in which inflammation subsides during recovery time, and another in which inflammatory activation is greater and increases during recovery time ( Table 2 ). This different kind of response suggests the relevance of individual functional inflammatory activation, which could identify patients with more aggressive peripheral arterial disease.
Finally, atherosclerosis is a multifaceted disease that involves several risk factors, and it is unlikely that a common pathogenic process operates in all patients.
Conclusion
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